Selected article for: "city spread and Hubei city"
Author: Gómez-Mesa, Juan Esteban; Galindo-Coral, Stephania; Montes, Maria Claudia; Martin, Andrés J. Muñoz
Title: THROMBOSIS AND COAGULOPATHY IN COVID-19
  • Cord-id: v5igmg3u
  • Document date: 2020_11_2
    • ID: v5igmg3u
    Snippet: Since December 2019, an outbreak of coronavirus disease 2019 (COVID-19) which initially occurred in the city of Wuhan, located in China's Hubei province, spread around the world and on 11 March 2020, the World Health Organization declared the new Coronavirus disease 2019 (COVID-19) as a pandemic. The presence of comorbidities (e.g.: cardiovascular disease, obesity), SIC score> 4, elevation of D-dimer (> 6 times the normal value), C-reactive protein, troponins and other DIC markers; is associated
    Document: Since December 2019, an outbreak of coronavirus disease 2019 (COVID-19) which initially occurred in the city of Wuhan, located in China's Hubei province, spread around the world and on 11 March 2020, the World Health Organization declared the new Coronavirus disease 2019 (COVID-19) as a pandemic. The presence of comorbidities (e.g.: cardiovascular disease, obesity), SIC score> 4, elevation of D-dimer (> 6 times the normal value), C-reactive protein, troponins and other DIC markers; is associated to a worse prognosis in hospitalized patients with severe COVD-19, reaching a hospital mortality of 42%. Initial anticoagulant treatment with LMWH has been shown to reduce mortality by 48% at 7 days and 37% at 28 days and achieve a significant improvement in the arterial oxygen pressure / inspired fraction of O2 (PaO2 / FiO2) by mitigating the formation of microthrombi and associated pulmonary coagulopathy.

    Search related documents:
    Co phrase search for related documents
    • active bleeding and liver kidney: 1
    • active bleeding and low molecular weight heparin: 1, 2, 3
    • active bleeding and low unfractionated: 1, 2
    • active bleeding and low unfractionated molecular weight heparin: 1, 2
    • active bleeding and lymphocyte neutrophil: 1
    • active bleeding and lymphocyte neutrophil ratio: 1
    • active cancer and acute ards respiratory distress syndrome: 1, 2
    • active cancer and liver kidney: 1, 2
    • active cancer and lymphocyte neutrophil: 1, 2, 3, 4
    • active cancer and lymphocyte neutrophil ratio: 1, 2
    • acute ards respiratory distress syndrome and additional benefit: 1, 2
    • acute ards respiratory distress syndrome and liver kidney: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35
    • acute ards respiratory distress syndrome and liver kidney function: 1
    • acute ards respiratory distress syndrome and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute ards respiratory distress syndrome and low unfractionated: 1
    • acute ards respiratory distress syndrome and low unfractionated molecular weight heparin: 1
    • acute ards respiratory distress syndrome and lung field: 1, 2, 3
    • acute ards respiratory distress syndrome and lymphocyte neutrophil: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32
    • acute ards respiratory distress syndrome and lymphocyte neutrophil ratio: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25